- Home
- IMNM vs HTD Comparison
IMNM vs HTD Comparison
Compare IMNM & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- HTD
- Stock Information
- Founded
- IMNM 2006
- HTD 2004
- Country
- IMNM United States
- HTD United States
- Employees
- IMNM N/A
- HTD N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- HTD Finance Companies
- Sector
- IMNM Health Care
- HTD Finance
- Exchange
- IMNM Nasdaq
- HTD Nasdaq
- Market Cap
- IMNM 806.1M
- HTD 807.8M
- IPO Year
- IMNM 2020
- HTD N/A
- Fundamental
- Price
- IMNM $9.52
- HTD $23.49
- Analyst Decision
- IMNM Strong Buy
- HTD
- Analyst Count
- IMNM 5
- HTD 0
- Target Price
- IMNM $28.60
- HTD N/A
- AVG Volume (30 Days)
- IMNM 1.2M
- HTD 92.3K
- Earning Date
- IMNM 03-27-2025
- HTD 01-01-0001
- Dividend Yield
- IMNM N/A
- HTD 8.59%
- EPS Growth
- IMNM N/A
- HTD N/A
- EPS
- IMNM N/A
- HTD N/A
- Revenue
- IMNM $10,129,000.00
- HTD N/A
- Revenue This Year
- IMNM N/A
- HTD N/A
- Revenue Next Year
- IMNM N/A
- HTD N/A
- P/E Ratio
- IMNM N/A
- HTD N/A
- Revenue Growth
- IMNM N/A
- HTD N/A
- 52 Week Low
- IMNM $8.97
- HTD $16.17
- 52 Week High
- IMNM $30.96
- HTD $22.13
- Technical
- Relative Strength Index (RSI)
- IMNM 40.66
- HTD 63.58
- Support Level
- IMNM $9.67
- HTD $23.11
- Resistance Level
- IMNM $10.68
- HTD $23.45
- Average True Range (ATR)
- IMNM 0.80
- HTD 0.23
- MACD
- IMNM -0.08
- HTD 0.03
- Stochastic Oscillator
- IMNM 0.34
- HTD 92.89
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.